Talvey (talquetamab-tgvs) -

This medication requires a valid prescription. Please refer to the ‘Prescription Guide’ for details.

Note: We can assist only if the medicine is unavailable in your country.”

Talvey (talquetamab-tgvs)

General Description

Talvey (talquetamab-tgvs) is prescribed for adults with multiple myeloma that has relapsed or is refractory after receiving at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody.¹ It was granted accelerated approval by the U.S. FDA.²

Getting Talvey (talquetamab-tgvs) in India

Talvey (talquetamab-tgvs)is approved in the U.S., Europe, and other countries, but it is not yet commercially available in India. However, eligible patients in India may access this important therapy through the Named Patient Program (NPP).

MitoGENE helps patients obtain Talvey (talquetamab-tgvs) legally and safely, in collaboration with their treating doctor. We assist with documentation, import coordination, and delivery—ensuring full compliance with Indian regulatory guidelines.

If you or a loved one needs Talvey (talquetamab-tgvs), MitoGENE is here to guide you through every step of the process.

Disease Indications:Multiple Myeloma

Manufacturer:Janssen Biotech

Usage:Subcutaneous

Medicine Approved by:

U.S. Food and Drug Administration (FDA)
European Medicines Agency (EMA)

Available Dosage Form & Package:

1 single-dose vial x 3 mg/1.5 mL (2 mg/mL)
1 single-dose vial x 40 mg/mL

Shipping:Cold Chain Shipping. Certain medicines can be affected by heat, light, or improper handling. Cold chain shipping uses temperature-controlled packaging and transport provided by specialized medical couriers to keep these medicines stable and effective. Due to the added care and equipment involved, this method is often more expensive than standard shipping.

What is Talvey (talquetamab-tgvs) used for?
Talvey (talquetamab-tgvs) is a prescription treatment for adult patients with relapsed or refractory multiple myeloma who have previously received at least four different therapies, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody.¹

Talvey is administered as a subcutaneous injection and is available in 3 mg/1.5 mL or 40 mg/mL dosage forms.¹

How does Talvey (talquetamab-tgvs) work?
Talvey is a bispecific antibody that simultaneously targets two key molecules:

GPRC5D, a protein found in high levels on multiple myeloma cells, and
CD3, a receptor on T cells—the immune cells responsible for attacking cancer.
By binding both targets, Talvey brings T cells into close contact with cancer cells, triggering the T cells to attack and destroy the malignant cells.³

Where is Talvey (talquetamab-tgvs) approved?
Talvey received accelerated approval from the U.S. FDA.² In the United States, its use is restricted under the TECVAYLI and TALVEY REMS program due to the risks of Cytokine Release Syndrome (CRS) and neurologic toxicity.⁴

In the European Union, the medicine is under review for marketing authorization and was granted a positive opinion recommending conditional approval in July 2023.⁵

References

Talvey: Pending EC decision | European Medicines Agency. European Medicines Agency, 20 July 2023.

Cindy P. TALVEY™ Overview. Janssen CarePath, 29 August 2023.

Talquetamab-tgvs for relapsed or refractory multiple myeloma. FDA, 9 August 2023, Accessed 25 September 2023.

Talquetamab-tgvs (Talvey) Drug Information. Understanding Cancer Immunotherapy Research, 17 August 2023.

TECVAYLI and TALVEY REMS, Accessed 25 September 2023.

Four Simple Steps to AccessTalvey (talquetamab-tgvs)

If Talvey (talquetamab-tgvs) is not yet approved or available commercially in your country, MitoGENE can help you access it through a legal pathway. Here’s how: